Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma

被引：0

作者：

S Yamasaki

R Suzuki

K Hatano

K Fukushima

H Iida

S Morishima

Y Suehiro

T Fukuda

N Uchida

H Uchiyama

H Ikeda

A Yokota

K Tsukasaki

H Yamaguchi

J Kuroda

H Nakamae

Y Adachi

K-i Matsuoka

Y Nakamura

Y Atsuta

J Suzumiya

机构：

[1] National Hospital Organization Kyushu Medical Center,Department of Hematology and Clinical Research Institute

[2] Shimane University Hospital,Department of Oncology and Haematology

[3] Jichi Medical University,Division of Hematology and Cell Therapy

[4] Rinku General Medical Center,Division of Hematology

[5] National Hospital Organization Nagoya Medical Center,Division of Cell Therapy

[6] Fujita Health University School of Medicine,Department of Hematology and Oncology

[7] National Hospital Organization Kyushu Cancer Center,Department of Hematology

[8] National Cancer Center Hospital,Division of Hematopoietic Stem Cell Transplantation

[9] Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital,Department of Hematology

[10] Japanese Red Cross Kyoto Daiichi Hospital,Department of Hematology

[11] Rheumatology and Clinical Immunology,Department of Gastroenterology

[12] Sapporo Medical University Hospital,Department of Hematology

[13] Chiba Aoba Municipal Hospital,Hematology Division

[14] National Cancer Center Hospital East,Department of Hematology

[15] Nippon Medical School,Division of Hematology and Oncology, Department of Medicine

[16] Kyoto Prefectural University of Medicine,Department of Hematology

[17] Osaka City University Hospital,Department of Internal Medicine

[18] Japan Community Health Care Organization Kobe Central Hospital,Division of Hematology and Oncology

[19] Okayama University Hospital,Third Department of Internal of Medicine

[20] Yamaguchi University School of Medicine,Department of Healthcare Administration

[21] Nagoya University Graduate School of Medicine and Japanese Data Center for Hematopoietic Cell Transplantation,undefined

来源：

Bone Marrow Transplantation | 2017年 / 52卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-AML/MDS) represent severe late effects in patients receiving hematopoietic cell transplantation (HCT) for lymphoma. The choice between high-dose therapy with autologous HCT and allogeneic HCT with reduced-intensity conditioning remains controversial in patients with relapsed lymphoma. We retrospectively analyzed incidence and risk factors for the development of t-AML/MDS in lymphoma patients treated with autologous or allogeneic HCT. A total of 13 810 lymphoma patients who received autologous (n=9963) or allogeneic (n=3847) HCT between 1985 and 2012 were considered. At a median overall survival (OS) of 52 and 46 months in autologous and allogeneic HCT groups, respectively, lymphoma patients receiving autologous HCT (1.38% at 3 years after autologous HCT) had a significant risk for developing t-AML/MDS compared to allogeneic HCT (0.37% at 3 years after allogeneic HCT, P<0.001). Significant risk factors for the development of t-AML/MDS after autologous and allogeneic HCT were high-stage risk at HCT (P=0.04) or secondary malignancies (P<0.001) and receiving cord blood stem cell (P=0.03) or involved field radiotherapy (P=0.002), respectively. Strategies that carefully select lymphoma patients for autologous HCT, by excluding lymphoma patients with high-stage risk at HCT, may allow the identification of individual lymphoma patients at particular high risk for t-AML/MDS.

引用

页码：969 / 976

页数：7

共 122 条

[21]

Lu D(2016)Long-term follow-up of therapy-related myelodysplasia and AML patients treated with allogeneic hematopoietic cell transplantation Bone Marrow Transplant. 51 771-777

[22]

Kroon M(2012)Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial Lancet 379 1791-1799

[23]

Neuberg D(2015)Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma N Engl J Med. 372 1598-1607

[24]

Tantravahi R(undefined)undefined undefined undefined undefined-undefined

[25]

Hake CR(undefined)undefined undefined undefined undefined-undefined

[26]

Graubert TA(undefined)undefined undefined undefined undefined-undefined

[27]

Fenske TS(undefined)undefined undefined undefined undefined-undefined

[28]

Ramadan SM(undefined)undefined undefined undefined undefined-undefined

[29]

Fouad TM(undefined)undefined undefined undefined undefined-undefined

[30]

Summa V(undefined)undefined undefined undefined undefined-undefined

← 1 2 3 4 5 6 7 8 9 10 →